Alana C. Keegan1,2, Sanuja Bose 2 , Katherine M. McDermott 2 ,Midori P. Starks White 2 , David P. Stonko2 , Danielle Jeddah3 , Eilat Lev-Ari 3 , Joanna Rutkowski 2 , Ronald Sherman2 , Christopher J. Abularrage 2 , Elizabeth Selvin 4 and Caitlin W. Hicks 2 *

1 Department of Surgery, Sinai Hospital of Baltimore, Baltimore, MD, United States, 2Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins University, Baltimore, MD, United States, 3Department of Clinical Development, Healthy.io Ltd., Tel Aviv, Israel, 4Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, United States

Background: Regular clinical assessment is critical to optimize lower extremity wound healing. However, family and work obligations, socioeconomic, transportation, and time barriers often limit patient follow-up. We assessed the feasibility of a novel, patient-centered, remote wound management system (Healthy.io Minuteful for Wound Digital Management System) for the surveillance of lower extremity wounds.

Methods: We enrolled 25 patients from our outpatient multidisciplinary limb preservation clinic with a diabetic foot ulcer, who had undergone revascularization and podiatric interventions prior to enrollment. Patients and their caregivers were instructed on how to use the digital management system and asked to perform one at-home wound scan per week for a total of 8 weeks using a smartphone application. We collected prospective data on patient engagement, smartphone app useability, and patient satisfaction.

Results: Twenty-five patients (mean age 65.5 ± 13.7 years, 60.0% male, 52.0% Black) were enrolled over 3 months. Mean baseline wound area was 18.0 ± 15.2 cm2 , 24.0% of patients were recovering from osteomyelitis, and post-surgical WiFi stage was 1 in 24.0%, 2 in 40.0%, 3 in 28.0%, and 4 in 8.00% of patients. We provided a smartphone to 28.0% of patients who did not have access to one that was compatible with the technology. Wound scans were obtained by patients (40.0%) and caregivers (60.0%). Overall, 179 wound scans were submitted through the app. The mean number of wound scans acquired per patient was 0.72 ± 0.63 per week, for a total mean of 5.80 ± 5.30 scans over the course of 8 weeks. Use of the digital wound management system triggered an early change in wound management for 36.0% of patients. Patient satisfaction was high; 94.0% of patients reported the system was useful.

Conclusion: The Healthy.io Minuteful for Wound Digital Management System is a feasible means of remote wound monitoring for use by patients and/or their caregivers.

KEYWORDS

diabetic foot ulcer (DFU), diabetes, smartphone application (app), telemedicine, technology, smartphone, diabetic foot

OPEN ACCESS

EDITED BY

Zhengyi Tang, Shanghai Jiao Tong University, China

REVIEWED BY

Rasoul Goli,

Urmia University of Medical Sciences, Iran Adam Isaac, Foot and Ankle Specialists of the MidAtlantic (FASMA), LLC, United States

*CORRESPONDENCE

Caitlin W. Hicks 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

RECEIVED 02 February 2023

ACCEPTED 09 May 2023

PUBLISHED 24 May 2023

CITATION

Keegan AC, Bose S, McDermott KM, Starks White MP, Stonko DP, Jeddah D, Lev-Ari E, Rutkowski J, Sherman R, Abularrage CJ, Selvin E and Hicks CW (2023) Implementation of a patientcentered remote wound monitoring system for management of diabetic foot ulcers. Front. Endocrinol. 14:1157518. doi: 10.3389/fendo.2023.1157518

COPYRIGHT

© 2023 Keegan, Bose, McDermott, Starks White, Stonko, Jeddah, Lev-Ari, Rutkowski, Sherman, Abularrage, Selvin and Hicks. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The significant glucose-lowering and weight-loss benefits achieved with tirzepatide, the first “twincretin” (long-acting dual GIP/GLP-1 receptor agonist) therapy, could challenge and change current type 2 diabetes management strategies, resulting in tighter glycaemic control and in earlier use of tirzepatide, according to this recently published review by Australian authors. In randomised controlled and open-label studies in the SURPASS clinical programme in people with type 2 diabetes, tirzepatide achieved greater glucose-lowering, weight loss and other metabolic benefits compared with placebo, semaglutide and basal insulins across a broad range of populations, with low rates of hypoglycaemia and with comparable adverse event and safety profiles to GLP-1 receptor agonists. Overall, 43–62% of people treated once weekly with the highest tirzepatide dose (15 mg) achieved normoglycaemia, defined as HbA1c <5.7% (<39 mmol/mol), the lower end of the prediabetes/non-diabetic hyperglycaemia range used in the USA. Up to half achieved normoglycaemia and weight loss of ≥5%, without hypoglycaemia. A separate review brings together the results of the patient-reported outcome measures used in the SURPASS programme studies, exploring the impact of tirzepatide treatment on overall quality of life, ability to perform physical activities of daily living and treatment satisfaction. Significant quality of life benefits were demonstrated with tirzepatide compared to placebo or active comparators.

Pam Brown GP in Swansea

Citation: Brown P (2023) “Twincretin” tirzepatide significantly SURPASSes comparator effects on glucose, weight and quality of life. Diabetes & Primary Care 25: 209–11

This report outlines the proceedings of an industry-sponsored symposium (held at the European Wound Management Association 2023 Conference) during which an international panel of scientific and clinical experts shared research data relating to the mechanism of action of negative pressure wound therapy (NPWT) and its clinical relevance. The speakers also shared their clinical experiences of using a canister-based, singleuse NPWT system in the management of both open wounds and closed surgical incision sites.

Speakers: (Clockwise from top left) Marino Ciliberti (chair), Amit Gefen , Anette Svensson Henriksson and Sanna Kouhia

Marino Ciliberti is MD Surgeon, Director of the Wound Care Centre, Rete Aziendale Di Riparazione Tissutale, Aslnapoli3sud, Gragnano, Campania, Italy;

Amit Gefen is Professor of Biomedical Engineering Herbert J Berman Chair in Vascular Bioengineering, Department of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel; Skin Integrity Research Group (SKINT), University Centre for Nursing and Midwifery, Department of Public Health and Primary Care, Ghent University, Ghent, Belgium; Department of Mathematics and Statistics, Faculty of Sciences, Hasselt University, Hasselt, Belgium;

Anette Svensson Henriksson is Senior Scientist, Research & Development, Mölnlycke Healthcare, Gothenburg, Sweden;

Sanna Kouhia is Consultant in Vascular Surgery, Consultant in General Surgery, Specialist in Wound Care, Espoo, Finland

Our companion article outlines how metformin use can lead to a clinically significant deficiency in vitamin B12, and describes the problems this can cause. In this comment, we outline a project conducted in four primary care practices that aimed to improve metformin-related vitamin B12 deficiency detection rates in people with diabetes.

Shafali Khanom

Medical Student, University of Sofia, Bulgaria

Mosammath Monira Khatun

Medical Student, Imperial College London

Reshma Rasheed

GP, Chapel Street Surgery, Billericay

Citation:

Khanom S, Khatun MM, Rasheed R (2023) Improving detection rates of vitamin B12 deficiency caused by metformin. Journal of Diabetes Nursing

[Early view publication]